Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanFRA:L74 -4.46%55 Median PS Value is €0.00 as of Sep. 01, 2026. GuruFocus rates FRA:L74 with a GF Score™ of 55/100. The stock has 3 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks worse than 1063828.72% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2026-09-01), WuXi XDC Cayman's share price is €7.50. WuXi XDC Cayman's Median PS Value is €0.00. Therefore, WuXi XDC Cayman's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for WuXi XDC Cayman's Median PS Value or its related term are showing as below:
FRA:L74's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.905 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
WuXi XDC Cayman (FRA:L74) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
WuXi XDC Cayman's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
7.50
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman Median PS Value Related Terms
WuXi XDC Cayman Median PS Value Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:L74 vs TMO, DHR, NTRA: Median PS Value Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.638.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (FRA:L74) has a Median PS Value of €0.00 as of Sep. 01, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on WuXi XDC Cayman and its competitors. According to the industry distribution chart, WuXi XDC Cayman ranks #999999 out of 94 companies in the Medical Diagnostics & Research industry.
Is WuXi XDC Cayman's Median PS Value too high?
WuXi XDC Cayman's current Median PS Value is €0.00. Based on the distribution chart, WuXi XDC Cayman ranks #999999 out of 94 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #999999 out of 94 companies for Median PS Value. This places WuXi XDC Cayman in the lower half of its industry. The industry median Median PS Value is 0.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.91, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (FRA:L74) has a current Median PS Value of €0.00. The current Median PS Value is €0.00. WuXi XDC Cayman's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For WuXi XDC Cayman (FRA:L74), the current Median PS Value is €0.00 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
55GF Score
Get the complete analysis for FRA:L74
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L74 has been successfully added to your 
